Israel’s anti-dumping campaign has stepped up a notch with the ministry of economy proposing levies of up to 175% on Canadian imports.

A report published by the ministry over the weekend outlined acceptable prices for named Canadian companies based on their cooperation with the report and prices in their domestic market. 

The move comes after an investigation into the suspected dumping of cheap Canadian cannabis into the Israeli market earlier this year amid concerns the volume of imported product may be damaging the local industry. 

In July, the ministry’s preliminary report proposed tariffs ranging from 63% to 369% depending on the companies involved. The final report proposes fees starting from 2% and rising to a maximum of 175%.

The new recommendations are subject to a final ruling from an advisory committee before being implemented.

Australian firms have been watching developments in Israel closely, with some believing the federal government should adopt similar measures.

Neurotech International

Neurotech International has appointed Dr Anthony Filippis as its new managing director and CEO starting in February 2025.

Dr Filippis is currently the chief operating officer of ASX-listed Percheron Therapeutics, a clinical stage biotechnology company with an ongoing Phase IIb clinical trial in the rare paediatric disease, Duchenne muscular dystrophy. 

With 25 years’ biotech experience, Neurotech described Dr Filippis an “internationally proven senior business leader with a deep understanding and knowledge of the biotech industry and capital markets”. 

Neurotech chairman Mark Davies added: “Anthony will bring to Neurotech a significant amount of experience across the life sciences sector, with an outstanding track record of partnering success and capital markets expertise. 

“We.. look forward to his contribution in… 2025, which is shaping up as an important year of delivery for Neurotech as we accelerate our regulatory development.”

Dr Filippis said he was looking forward to working with the Neurotech team and board to progress development of the firm’s broad-spectrum cannabinoid drug therapy NTI164 and provide new treatment options for patients.

Source: Cannabiz